Solutionreach vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Patient engagement and communication platform for dental, medical, and optical practices with 400+ PMS integrations. Lehi UT; founded 2000;
About
Solutionreach is a Lehi, Utah-based patient engagement platform that has served dental, medical, optometry, and specialty healthcare practices with automated appointment reminders, patient messaging, satisfaction surveys, and online review management since 2000. As one of the earliest companies to build technology specifically for healthcare practice patient communication, Solutionreach has established a large installed base across independent practices and group practices in the United States. The platform integrates with over 400 practice management and EHR systems, triggering automated patient communication workflows based on appointment data, recall schedules, and clinical events—without requiring manual staff intervention for each individual patient interaction.\n\nSolutionreach's patient retention capabilities are central to its value proposition for healthcare practices. Research consistently shows that automated recall outreach significantly increases the percentage of patients who return for follow-up care and preventive appointments, and Solutionreach's multi-channel recall sequences—combining text, email, and phone reminders sent at configurable intervals—help practices reduce the attrition that erodes practice revenue over time. The platform's satisfaction survey module automatically collects patient feedback after appointments and routes positive responses to review sites while flagging negative feedback for internal service recovery, helping practices manage their online reputation systematically.\n\nSolutionreach has expanded its platform with online scheduling, telehealth integration, and digital patient intake forms to address the growing patient expectation for digital access to healthcare services. The company also offers practice benchmarking through aggregated data insights that allow practices to compare their recall rates, no-show rates, and online review volumes against peers in their specialty and geography. Solutionreach competes with Weave, Lighthouse 360, and RevenueWell in the dental and multi-specialty patient engagement market, differentiating on its depth of EHR and PMS integrations and its long track record with independent practice customers.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.